Chu Yu-Ju, Jeng Wen-Juei, Pan Mei-Hung, Hu Hui-Han, Luo Wen-Sheng, Su Chien-Yu, Chiang Chen-Tse, Jen Chin-Lan, Chen Chien-Jen, Yang Hwai-I
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan.
J Gastroenterol. 2022 Jun;57(6):423-432. doi: 10.1007/s00535-022-01874-8. Epub 2022 Apr 22.
In chronic hepatitis B virus (HBV) infection, earlier seroclearance of hepatitis B e antigen (HBeAg) is associated with more favorable outcomes. Soluble programmed cell death 1 (sPD-1) has been implicated in higher viral load and hepatocellular carcinoma. We investigated the association between sPD-1 levels and spontaneous HBeAg seroclearance.
Baseline serum samples from 488 HBeAg-seropositive patients in the REVEAL-HBV cohort were tested for sPD-1 levels. Among them, 329 with available follow-up serum samples were further assayed. Multivariate Cox regression analysis was used to estimate the adjusted rate ratio (aRR) and 95% confidence interval (CI) with adjustment of host and viral factors. The 66th percentile and an annual reduction of ≥ 10% were used as the cut-off point for baseline sPD-1 levels (high/low) and sPD-1 trajectory (decline/no decline), respectively.
Lower baseline sPD-1 levels [aRR (95% CI): 2.19 (1.47-3.27)] and long-term decline in sPD-1 levels [aRR (95% CI): 4.08 (2.79-5.97)] were both independent predictors for HBeAg seroclearance. However, further stratification analysis by HBV genotype showed that lower baseline sPD-1 levels were significantly associated with HBeAg seroclearance only in genotype C infection [aRR (95% CI): 4.47 (2.38-8.37)] but not in genotype B infection. On the other hand, long-term decline in sPD-1 levels was predictive for HBeAg seroclearance regardless of HBV genotype with aRR (95% CI) of 4.62 (2.71-7.88) and 2.95 (1.68-5.17), respectively, for genotypes B and C.
Serum sPD-1 levels may serve as a novel immunological predictor for spontaneous HBeAg seroclearance in patients with chronic hepatitis B.
在慢性乙型肝炎病毒(HBV)感染中,乙型肝炎e抗原(HBeAg)的早期血清学清除与更有利的预后相关。可溶性程序性细胞死亡蛋白1(sPD-1)与更高的病毒载量和肝细胞癌有关。我们研究了sPD-1水平与HBeAg自发血清学清除之间的关联。
对REVEAL-HBV队列中488例HBeAg血清学阳性患者的基线血清样本进行sPD-1水平检测。其中,329例有可用随访血清样本的患者进一步进行检测。采用多因素Cox回归分析,在调整宿主和病毒因素的情况下估计调整后的率比(aRR)和95%置信区间(CI)。分别将第66百分位数和每年下降≥10%作为基线sPD-1水平(高/低)和sPD-1轨迹(下降/未下降)的截断点。
较低的基线sPD-1水平[aRR(95%CI):2.19(1.47-3.27)]和sPD-1水平的长期下降[aRR(95%CI):4.08(2.79-5.97)]均为HBeAg血清学清除的独立预测因素。然而,按HBV基因型进行的进一步分层分析显示,仅在C基因型感染中,较低的基线sPD-1水平与HBeAg血清学清除显著相关[aRR(95%CI):4.47(2.38-8.37)],而在B基因型感染中则不然。另一方面,无论HBV基因型如何,sPD-1水平的长期下降均对HBeAg血清学清除具有预测性,B和C基因型的aRR(95%CI)分别为4.62(2.71-7.88)和2.95(1.68-5.17)。
血清sPD-1水平可能作为慢性乙型肝炎患者HBeAg自发血清学清除的一种新型免疫预测指标。